Literature DB >> 8975852

Pulmonary hypertension after operations for congenital heart disease: analysis of risk factors and management.

K Bando1, M W Turrentine, T G Sharp, Y Sekine, T X Aufiero, K Sun, E Sekine, J W Brown.   

Abstract

BACKGROUND: Management of pulmonary hypertension, a potentially fatal complication of operations to correct congenital heart disease, has evolved through the last 15 years. Monitoring of pulmonary arterial pressure and mixed venous saturation became available, and prophylactic use of alpha-blockers and other vasodilators increased. This study examines risk factors for morbidity and mortality from pulmonary hypertension after operations to correct congenital heart disease and evaluates the impact of management changes on outcomes.
METHODS: By means of multivariable logistic regression analysis, 880 high-risk patients with congenital heart disease (of 2484 patients undergoing cardiopulmonary bypass between January 1980 and December 1994) were analyzed to determine which were at risk for postoperative pulmonary hypertension and its associated morbidity and mortality.
RESULTS: Patients with atrioventricular canal (n = 182), truncus arteriosus (n = 47), total anomalous pulmonary venous connection (n = 90), transposition of great arteries (n = 97), hypoplastic left heart syndrome (n = 50), and ventricular septal defect (n = 414) demonstrated a higher risk of postoperative pulmonary hypertension. By multivariable logistic regression, preoperative pulmonary hypertension (p < 0.0001), absence of mixed venous saturation monitoring (p < 0.0001), and absence of prophylactic alpha-blockade (p = 0.0004) significantly increased postoperative pulmonary hypertension. Preoperative pulmonary hypertension (p < 0.001) and absence of prophylactic alpha-blockers (p = 0.0004) were significant risk factors for in-hospital death related to pulmonary hypertension. Repair at older age (except in the case of total anomalous pulmonary venous connection) was a significant risk for postoperative pulmonary hypertension (p = 0.03).
CONCLUSION: Mixed venous saturation monitoring and alpha-receptor blockade reduced the incidence of pulmonary hypertension after operations for congenital heart disease. Early definitive repair reduced morbidity and mortality from postoperative pulmonary hypertension.

Entities:  

Mesh:

Year:  1996        PMID: 8975852     DOI: 10.1016/S0022-5223(96)70019-3

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  20 in total

1.  Postoperative Inhaled Nitric Oxide Does Not Decrease Length of Stay in Pediatric Cardiac Surgery Admissions.

Authors:  Joshua Wong; Rohit S Loomba; Lee Evey; Ronald A Bronicki; Saul Flores
Journal:  Pediatr Cardiol       Date:  2019-08-24       Impact factor: 1.655

2.  Do preoperative haemodynamic data and reactivity test predict the postoperative reversibility of pulmonary arterial hypertension in patients with large ventricular septal defect and borderline operability?

Authors:  Anuradha Sridhar; Raghavan Subramanyan; Nithya Lakshmi; Farida Farzana; Ravi Ranjan Tripathi; Rajasekaran Premsekar; Shanthi Chidambaram Pillai; Soman Rema Krishna Manohar; Ravi Agarwal; Kotturathu Mammen Cherian
Journal:  Heart Asia       Date:  2013-08-21

3.  Early therapeutic experience with the endothelin antagonist BQ-123 in pulmonary hypertension after congenital heart surgery.

Authors:  B Prendergast; D E Newby; L E Wilson; D J Webb; P S Mankad
Journal:  Heart       Date:  1999-10       Impact factor: 5.994

4.  Comparison of inhaled nitric oxide with aerosolized iloprost for treatment of pulmonary hypertension in children after cardiopulmonary bypass surgery.

Authors:  Tsvetomir Loukanov; Dietrich Bucsenez; Wolfgang Springer; Christian Sebening; Helmut Rauch; Eva Roesch; Matthias Karck; Matthias Gorenflo
Journal:  Clin Res Cardiol       Date:  2011-02-13       Impact factor: 5.460

5.  Functional interaction between Foxd3 and Pax3 in cardiac neural crest development.

Authors:  Brian L Nelms; Elise R Pfaltzgraff; Patricia A Labosky
Journal:  Genesis       Date:  2010-12-22       Impact factor: 2.487

6.  Postoperative use of oral sildenafil in pediatric patients with congenital heart disease.

Authors:  Ju Yeon Uhm; Won-Kyoung Jhang; Jeong-Jun Park; Dong-Man Seo; Sung-Cheol Yun; Tae-Jin Yun
Journal:  Pediatr Cardiol       Date:  2010-01-07       Impact factor: 1.655

7.  Total anomalous pulmonary venous connection: post operative problems and management.

Authors:  Sandeep Khanna; Minati Choudhury; Usha Kiran
Journal:  Indian J Anaesth       Date:  2009-02

Review 8.  Pulmonary Hypertension.

Authors:  Peter Oishi; Jeffrey R Fineman
Journal:  Pediatr Crit Care Med       Date:  2016-08       Impact factor: 3.624

9.  Perioperative sildenafil therapy for pulmonary hypertension in infants undergoing congenital cardiac defect closure.

Authors:  Ashraf A H El Midany; Ezzeldin A Mostafa; Sherif Azab; Ghada A Hassan
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-08-28

Review 10.  Perioperative pharmacological management of pulmonary hypertensive crisis during congenital heart surgery.

Authors:  Nathan Brunner; Vinicio A de Jesus Perez; Alice Richter; François Haddad; André Denault; Vanessa Rojas; Ke Yuan; Mark Orcholski; Xiaobo Liao
Journal:  Pulm Circ       Date:  2014-03       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.